Business
Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026
FREMONT, Calif., April 21, 2026--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the successful presentation of clinical data at the American Association for Cancer Research (AACR) Annual Meeting. The data, spanning one oral podium presentation and three posters, underscore the use of the NeXT Personal ultrasensitive ctDNA assay in monitoring treatment response, identifying early recurrence, and tracking the emergence of therapy resistance.
About this update from Personalis, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":240,"url":"https://media.zenfs.com/en/business-wire.com/b717a36dba3e980f1320abedd0d59dbf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8TFuSf21nhnNz4MTQ4J5fA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/b717a36dba3e980f1320abedd0d59dbf","width":480,"height":240}},"lazy":false},{"type":"text","content":"Podium presentation on NeXT Personal® monitoring neoadjuvant therapy in colorectal cancer;","length":90,"tagName":"p","attribs":{}},{"type":"text","content":"Real-world data from 10,000 patients reinforce industry-leading sensitivity;","length":76,"tagName":"p","attribs":{}},{"type":"text","content":"Data presented for a new NeXT Personal feature for monitoring resistance mutations","length":82,"tagName":"p","attribs":{}},{"type":"text","content":"FREMONT, Calif., April 21, 2026--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the successful presentation of clinical data at the American Association for Cancer Research (AACR) Annual Meeting. The data, spanning one oral podium presentation and three posters, underscore the use of the NeXT Personal ultrasensitive ctDNA assay in monitoring treatment response, identifying early recurrence, and tracking the emergence of therapy resistance.","length":516,"tagName":"p"},{"type":"text","content":"Neoadjuvant Monitoring in Colorectal Cancer. A highlight was the oral podium presentation of the NEOPRISM-CRC trial, delivered by Dr. Jiang from the University College London, which utilized NeXT Personal to monitor patients with high-risk stage II-III dMMR/MSI-H colorectal cancer (CRC) receiving neoadjuvant pembrolizumab. In addition to 100% sensitivity for disease at baseline, the study identified three distinct groups of patient response to neoadjuvant treatment: super molecular responders, dynamic molecular responders, and poor molecular responders. Notably, 100% of "super molecular responders"—those who cleared ctDNA by the second cycle of treatment—also achieved pathological complete response (pCR). Conversely, of "poor molecular responders"—patients with relatively stable ctDNA levels during neoadjuvant treatm...